Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort

被引:13
作者
Van Muijen, Marloes. E. [1 ,2 ]
Thomas, Sarah E. [1 ,2 ]
Groenewoud, Hans M. M. [2 ,3 ]
Otero, Marisol E. [1 ,2 ]
Ossenkoppele, Paul M. [4 ]
Njoo, Marcellus D. [4 ]
Dodemont, Sharon R. P. [5 ]
Kop, Else N. [6 ]
Berends, Maartje A. M. [7 ]
Koetsier, Marjolein I. A. [8 ]
Mommers, Johannes M. [9 ]
Korver, John E. M. [10 ]
Tupker, Ron A. [11 ]
De Bruin-Weller, Marjolein S. [12 ]
Weppner-Parren, Lizelotte J. M. T. [13 ]
Peters, Bas [14 ]
Kleinpenning, Marloes M. [15 ]
Kuijpers, Astrid L. A. [16 ]
Arnold, W. Peter [17 ]
Van Lumig, Paula P. M. [18 ]
Van den Reek, Juul M. P. A. [1 ,2 ]
De Jong, Elke M. G. J. [1 ,2 ,19 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr Radboudumc, Dept Dermatol, Mailbox 9101, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr Radboudumc, Radboud Inst Hlth Sci RIHS, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr Radboudumc, Dept Hlth Evidence, Nijmegen, Netherlands
[4] Ziekenhuisgroep Twente, Dept Dermatol, Almelo Hengelo, Netherlands
[5] Catharina Hosp, Eindhoven, Netherlands
[6] Bernhoven Ziekenhuis, Uden, Netherlands
[7] Slingeland Ziekenhuis, Doetinchem, Netherlands
[8] Gelre Ziekenhuizen, Apeldoorn, Netherlands
[9] St Anna Ziekenhuis, Geldrop, Netherlands
[10] Amphia Ziekenhuis, Breda, Netherlands
[11] St Antonius Hosp, Nieuwegein, Netherlands
[12] Utrecht Med Ctr, Utrecht, Netherlands
[13] Jeroen Bosch Ziekenhuis, Shertogenbosch, Netherlands
[14] Ziekenhuis Rijnstate, Arnhem, Netherlands
[15] Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands
[16] Maxima Med Ctr, Eindhoven, Netherlands
[17] Ziekenhuis Gelderse Vallei, Ede, Netherlands
[18] Maastricht UMC, Maastricht, Netherlands
[19] Radboud Univ Nijmegen, Nijmegen, Netherlands
关键词
psoriasis; biologics; PASI; real-world evidence; effectiveness; observational studies; EFFICACY; ETANERCEPT; SAFETY; AGENTS;
D O I
10.2340/actadv.v102.206
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Real-world evidence, directly comparing the effectiveness of interleukin (IL)17-inhibitors, IL23-inhibitors, tumour necrosis factor alpha (TNF-alpha)-inhibitors and an IL12/23-inhibitor in psoriasis, is scarce. The aim of this study was to directly compare the first-year effectiveness of biologic therapies for psoriasis, corrected for confounders. This prospective, multicentre cohort study assessed BioCAPTURE data on etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab in 1,080 treatment episodes of 700 patients with psoriasis. The course of the mean absolute Psoriasis Area and Severity Index (PASI) and the proportion of patients who achieved PASI90/PASI75 were compared using linear mixed models and mixed logistic regression models respectively, corrected for baseline PASI, biologic naivety, and weight. Patients treated with adalimumab, ustekinumab, secukinumab, ixekizumab, or guselkumab all had a significantly lower mean PASI after 12 months compared with etanercept, and significantly higher overall odds of reaching PASI90 than those treated with etanercept. Patients treated with ixekizumab or guselkumab also had higher probabilities of reaching PASI90 than adalimumab, ustekinumab, and secukinumab. Relative to randomized controlled trials, the proportions of patients who reached PASI90/75 were lower in this real-world study.
引用
收藏
页数:7
相关论文
共 32 条
  • [1] Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
    Bai, Fan
    Li, Gang Gang
    Liu, Qingmin
    Niu, Xinwu
    Li, Ruilian
    Ma, Huiqun
    [J]. JOURNAL OF IMMUNOLOGY RESEARCH, 2019, 2019
  • [2] Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study
    Bissonnette, R.
    Luger, T.
    Thaci, D.
    Toth, D.
    Messina, I.
    You, R.
    Guana, A.
    Fox, T.
    Papavassilis, C.
    Gilloteau, I.
    Mrowietz, U.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (04) : 1033 - 1042
  • [3] PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis
    Carrera, Carlo Giovanni
    Dapavo, Paolo
    Malagoli, Piergiorgio
    Naldi, Luigi
    Arancio, Luisa
    Gaiani, Francesca
    Egan, Colin Gerard
    Di Mercurio, Marco
    Cattaneo, Angelo
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (05) : 481 - 486
  • [4] Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study
    Chiricozzi, Andrea
    Balato, Anna
    Conrad, Curdin
    Conti, Andrea
    Dapavo, Paolo
    Ferreira, Paulo
    Gaiani, Francesca Maria
    Leite, Luiz
    Malagoli, Piergiorgio
    Mendes-Bastos, Pedro
    Megna, Matteo
    Messina, Francesco
    Nidegger, Alessia
    Odorici, Giulia
    Panduri, Salvatore
    Piaserico, Stefano
    Piscitelli, Leonardo
    Prignano, Francesca
    Ribero, Simone
    Valerio, Joana
    Torres, Tiago
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (05) : 476 - 483
  • [5] Real-world experience versus clinical trials: pros and cons in psoriasis therapy evaluation
    Cinelli, Eleonora
    Fabbrocini, Gabriella
    Megna, Matteo
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (03) : E107 - E108
  • [6] Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study
    Colombo, Delia
    Bianchi, Luca
    Fabbrocini, Gabriella
    Corrao, Salvatore
    Offidani, Annamaria
    Stingeni, Luca
    Costanzo, Antonio
    Pellacani, Giovanni
    Peris, Ketty
    Bardazzi, Federico
    Argenziano, Giuseppe
    Ruffolo, Silvana
    Dapavo, Paolo
    Carrera, Carlo
    Fargnoli, Maria Concetta
    Parodi, Aurora
    Romanelli, Marco
    Malagoli, Piergiorgio
    Talamonti, Marina
    Megna, Matteo
    Raspanti, Massimo
    Paolinelli, Matteo
    Hansel, Katharina
    Narcisi, Alessandra
    Conti, Andrea
    De Simone, Clara
    Chessa, Marco Adriano
    De Rosa, Alina
    Provenzano, Eugenio
    Ortoncelli, Michela
    Moltrasio, Chiara
    Fidanza, Rosaria
    Burlando, Martina
    Tonini, Annalisa
    Gaiani, Francesca Maria
    Simoni, Lucia
    Ori, Alessandra
    Fiocchi, Martina
    Zagni, Emanuela
    [J]. DERMATOLOGIC THERAPY, 2022, 35 (01)
  • [7] Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study
    Deza, G.
    Notario, J.
    Lopez-Ferrer, A.
    Vilarrasa, E.
    Ferran, M.
    del Alcazar, E.
    Carrascosa, J. M.
    Corral, M.
    Salleras, M.
    Ribera, M.
    Puig, L.
    Pujol, R. M.
    Vidal, D.
    Gallardo, F.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (03) : 553 - 559
  • [8] Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients
    Drerup, Katharina A.
    Seemann, Claudia
    Gerdes, Sascha
    Mrowietz, Ulrich
    [J]. DERMATOLOGY, 2022, 238 (04) : 615 - 619
  • [9] Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
    Egeberg, A.
    Ottosen, M. B.
    Gniadecki, R.
    Broesby-Olsen, S.
    Dam, T. N.
    Bryld, L. E.
    Rasmussen, M. K.
    Skov, L.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (02) : 509 - 519
  • [10] Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy
    Galluzzo, M.
    Caldarola, G.
    De Simone, C.
    Bernardini, N.
    Moretta, G.
    Pallotta, S.
    Botti, E.
    Campione, E.
    Pirro, F.
    Potenza, C.
    Bianchi, L.
    Peris, K.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (09) : 1299 - 1309